C2N Diagnostics Receives Breakthrough Device Designation from U.S. FDA for Blood Test to Screen for Alzheimer’s Disease Risk

30 January 2019

Ampersand Health and MediQuire, Inc. are pleased to announce a strategic partnership to structure and drive success in value-based contracts for Ampersand Health and its payers using a data-driven